INTRODUCTION
Microscopic colitis (MC) is a common cause of chronic watery diarrhea and gastrointestinal symptoms ( 1 ) . Diarrhea can range from mild and intermittent to severe and persistent, and can adversely aff ect quality of life, especially if there is signifi cant fecal incontinence ( 1 ) . Patients with severe symptoms are oft en treated with corticosteroids ( 1 ) . In randomized clinical trials, the response rate to corticosteroid therapy is high, but a signifi cant number of patients experience recurrence aft er corticosteroid withdrawal ( 2 -8 ) . No studies have directly compared the eff ectiveness of prednisone with budesonide. A recent metaanalysis included six induction trials with nine subjects treated with prednisolone, 82 treated with budesonide, and 77 treated with placebo ( 9 ) . Response was reported in 80 % in the budesonide group vs. 26 % in the placebo group. In the small study of subjects treated with prednisolone, no statistically signifi cant diff erence in response was seen compared with those treated with placebo ( 8 ) .
Th ese studies are limited because they mostly involve patients with collagenous colitis (CC). Furthermore, the results of clinical trials are not always representative of clinical experience, in part because of potential referral bias and exclusion criteria. No studies have directly compared outcomes in patients treated with budesonide to those treated with prednisone. Th us, this population-based study aimed to investigate the clinical characteristics and outcomes in a cohort of patients with both CC and lymphocytic colitis (LC) who were treated with corticosteroids. We also aimed to compare outcomes in patients treated with prednisone to those treated with budesonide. To evaluate the outcomes of corticosteroid-treated microscopic colitis (MC) in a population-based cohort, and to compare these outcomes in patients treated with prednisone or budesonide.
Outcomes of Patients

METHODS:
A historical cohort study of Olmsted County, Minnesota residents diagnosed with collagenous or lymphocytic colitis (LC) between 1986 and 2010 was performed using the Rochester Epidemiology Project.
RESULTS:
Of 315 patients with MC, 80 (25.4 % ) were treated with corticosteroids. ( 10 ) . Th e REP therefore allows investigators to follow subjects through their outpatient and hospitalization contacts across all local medical facilities, regardless of where the care was delivered and of insurance status ( 10 ) . We identified potential cases of MC using ICD-9 codes 558.9, 561, and 563.9, and a code that is specific to our institution for " non-infectious colitis. " An additional search was performed using the Mayo Clinic Pathology database. Using this strategy, which was used previously to identify cases in an epidemiological study of MC in Olmsted County ( 11 ), records for potential subjects were identified and then reviewed to confirm cases as defined below. This study was approved by both the Mayo Clinic and Olmsted Medical Center Institutional Review Boards.
Adults 18 years or older, who provided research authorization, were identifi ed based on the presence of diarrhea (greater than three loose stools in 24 h), normal endoscopic colonic appearance, and histopathological evidence of CC or LC ( 1 ) . Individuals who did not have diarrhea, who had an alternative explanation for their diarrhea such as an infectious etiology or infl ammatory bowel disease, or who had no evidence of MC on review of their biopsies were excluded. From confi rmed cases, we identifi ed those who were treated with corticosteroids (either budesonide or prednisone). Demographic and clinical information was abstracted by chart review, including initial corticosteroid start and stop date, type of corticosteroid and dose, response, the date of recurrence, and the need for corticosteroid maintenance.
Response was defi ned as improvement in bowel movements during the initial course of corticosteroid treatment (assessed at 8 + 1 weeks aft er initiation of steroid treatment). Complete response was defi ned as resolution of diarrhea, whereas partial response was defi ned as at least 50 % improvement in number of bowel movements. Improvement of < 50 % was considered nonresponse. Recurrence was defi ned as the recurrence of diarrhea aft er improvement during the fi rst treatment course of corticosteroids. Time to recurrence was calculated from the day of steroid discontinuation (in those who responded) until the day of recurrent symptoms. Long-term corticosteroid maintenance was defi ned as restarting this treatment for a recurrence of MC. Th e duration of follow-up was determined from the date of corticosteroid initiation to the date of last follow-up.
Th ere were seven patients who were treated with oral prednisone for other conditions; one each for aortitis, polymyalgia rheumatica, chronic obstructive pulmonary disease, chronic urticaria, and sacroiliitis, and two with undiff erentiated connective tissue disease. Th ese patients were included in our analyses as we were able to determine the eff ect of corticosteroid therapy on their colitis symptoms.
Statistical analyses were performed using JMP version 9.0.1. Diff erences in treatment response at 8 weeks were compared using χ 2 -analysis. Cox proportional hazard analysis was used to compare time to recurrence in patients treated with prednisone to those treated with budesonide.
RESULTS
Of 315 Olmsted County residents diagnosed with MC from 1986 to 2010, 80 patients (25.4 % ) were treated with corticosteroids. Th e median age at the time of MC diagnosis was 66.5 years (range, 16 -95) and 78.7 % were female. Th e clinical characteristics of these patients, including severity of symptoms at the time of corticosteroid initiation, are outlined in Table 1 . were treated with budesonide. Th e initial median daily dose of budesonide was 9 mg (range, 6 -9 mg) and the initial median dose of prednisone was 25 mg (range, 7 -40 mg). Before the initiation of either budesonide or prednisone, patients had failed loperamide, bismuth subsalicylate, mesalamine, diphenoxylate / atropine, psyllium, fi ber, and cholestyramine.
Six patients were lost to follow-up. In the remaining 74 patients, 56 had complete response (75.7 % ) and 15 had partial response (20.3 % ). Of the 17 patients treated with prednisone, 9 had a complete response (52.9 % ), 7 had a partial response (41.2 % ), and 1 had no response (5.9 % ). Of the 57 treated with budesonide, 47 had a complete response (82.5 % ), 8 had a partial response (14.0 % ), and 2 had no response (3.5 % ). Th e rate of complete response was higher in patients treated with budesonide compared with those treated with prednisone ( P = 0.02; odds ratio, 4.2, 95 % CI, 1.3 -13.5). Th e rate of complete response to corticosteroid therapy was similar in patients with LC and CC (77.8 vs. 73.4 % , P = 0.68; odds ratio, 1.25, 95 % CI, 0.43 -3.63). One patient who failed budesonide responded to prednisone. No patient switched from prednisone to budesonide.
Follow-up data were available in 73 patients, with a median duration of follow-up of 4 years (range 0.2 -14 years). Patients treated with budesonide were less likely to recur than those treated with prednisone (hazard ratio, 0.38; 95 % CI, 0.18 -0.85; P = 0.02). Th e median time to recurrence aft er stopping prednisone was 21.0 days, which was signifi cantly shorter than aft er stopping budesonide (63.5 days, P = 0.02) ( Figure 1 ) .
Of the three patients who did not respond to corticosteroids, one was lost to follow-up aft er failing budesonide, one was maintained on diphenoxylate / atropine aft er failing sulfasalazine, bismuth subsalicylate, and budesonide, and one was maintained
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on a restricted diet and diphenoxylate / atropine aft er failing budesonide.
Of the 71 patients who responded, 50 (70.4 % ) had a recurrence aft er steroid discontinuation. Aft er 397 person-years of follow-up in the 73 patients with long-term data, 47 (64.4 % ) required maintenance with corticosteroids. Th ere were 35 patients who went on maintenance budesonide therapy, 5 (14 % ) at an initial dose of 3 mg / day, 7 (20 % ) at a dose of 6 mg / day, and 23 (66 % ) at a dose of 9 mg / day. Many of these patients had their dose of budesonide tapered during follow-up, with a maintenance dose of 3 mg / day in 29 (83 % ), 6 mg / day in 4 (11 % ), and 9 mg / day in only 2 (6 % ). Of the 12 patients in the prednisone group, the initial maintenance dose was 7 mg / day in 2 patients (17 % ), 20 mg / day in 5 (41 % ), 40 mg / day in 3 (25 % ), and 50 mg / day in 2 (17 % ). All patients had tapering of their dose during maintenance therapy, with most patients maintained on 5 mg / day or less. Th e lowest maintenance dose of prednisone was 2 mg / day in 2 patients (17 % ), 4 mg / day in 1 (8 % ), 5 mg / day in 6 (50 % ), 10 mg / day in 1 (8 % ), 30 mg / day in 1 (8 % ), and 50 mg / day in 1 (8 % ) . Th e median duration of prednisone maintenance therapy was 982 days (range 38 -4721 days). However, the longer periods of prednisone therapy are confounded in several patients as prednisone was also used long term for some of the other conditions mentioned above. Th e median duration of budesonide maintenance therapy was 87 days (range 2 -2215 days). Th ree other patients with a recurrence were maintained on loperamide, bismuth subsalicylate, and mesalamine, respectively. No patients received steroid sparing therapy.
DISCUSSION
In this population-based cohort study, the use of cortico steroid therapy for MC increased significantly over time, from 0 % from 1986 -1990 to 62.5 % from 2006 -2010. Budesonide was used more commonly than prednisone, and was more effective in terms of a higher response rate, a lower rate of recurrence, and a longer time to recurrence. Prior studies assessing budesonide therapy have mostly included patients with CC ( 2 -7 ), while our study had equal numbers of patients with LC and CC.
Randomized controlled trials evaluating budesonide in the treatment of MC have shown a high response rate as well as a high rate of relapse. In CC, response rates have ranged from 57 to 100 % , with a recurrence rate of 80 % ( 2,3,7 ) . In LC, response to budesonide was seen in 86 % vs. 48 % with placebo ( P = 0.01), with 44 % of patients experiencing a recurrence aft er discontinuation of budesonide ( 8 ) . Similarly, our study demonstrated a complete response rate to budesonide of 83 % and a recurrence rate of 70 % . A prior randomized, blinded study concluded that short-term (2 weeks) prednisolone (50 mg / day) was not superior to placebo in patients with CC, although that study was underpowered (12 subjects total) ( 2 ) .
Two randomized controlled maintenance trials have demonstrated that budesonide is superior to placebo for maintaining remission, at least through 6 months, although the relapse rate was still high aft er discontinuation of prolonged therapy ( 5, 6 ) . In one study, patients received open-label budesonide induction and were then randomized to maintenance therapy with budesonide, 6 mg / day, or placebo. Of the patients treated with budesonide, 76.5 % remained in remission at 24 weeks vs. 12 % treated with placebo ( 5 ). In a similar study, 65 % of patients treated with budesonide maintained remission compared with 26 % treated with placebo ( 6 ). Our experience was similar to these results, with a majority of our patients being successfully maintained on budesonide therapy.
Enteric-coated budesonide was approved by the FDA for clinical use in October 2001. Th ereaft er, there was a decrease in the use of prednisone and an increase in the use of budesonide in this cohort. Th ere was a better response rate and lower recurrence rate Data are reported as number and percent except for age. 
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Outcomes of steroid treatment in MC with budesonide than prednisone, although these results should be interpreted with caution as patients were not randomized to treatment, and in some patients the dose of prednisone was relatively low. Budesonide has fewer corticosteroid-related adverse eff ects than prednisone, although the risk of side eff ects may be increased in those with liver disease or those who drink grapefruit juice ( 13 ) . In patients on long-term budesonide, monitoring of bone density, blood pressure, and blood glucose is recommended ( 13 ) . As part of our standard practice with long-term maintenance corticosteroids, including budesonide, patients undergo a DEXA scan and have their blood pressure, blood glucose, and vision monitored. In addition, patients are educated on the importance of daily calcium and vitamin D supplementation.
In conclusion, the use of corticosteroids has become increasingly common in patients with MC. Patients treated with corticosteroids for MC have a high response rate and a signifi cant risk of recurrence aft er corticosteroid withdrawal, oft en requiring long-term corticosteroid maintenance treatment. Budesonide had a higher response rate than prednisone, a lower risk of recurrence, and a longer time to recurrence.
